Researchers at Nankai University have developed the world’s first bionic neuromorphic auditory nerve interface, a device designed to bypass damaged natural pathways to restore hearing. Published in Nature Materials, the technology aims to address sensorineural hearing loss—a condition currently affecting approximately 3 percent of the global population.
Nankai University’s Bionic Interface
The device, created by a team led by Professor Xu Wentao at Nankai University, functions as an electronic bridge. By bypassing broken or missing auditory nerve fibers, the interface delivers processed sound signals directly to the brain’s neural pathways. Conventional hearing restoration methods often struggle in noisy environments because they rely on fixed timing circuits and limited electrode counts, which fail to replicate the natural auditory system’s ability to filter out background noise.
“Our long-term core goal is building an artificial nerve that can select, analyze and encode valuable audio information just like real biological tissue, shifting hearing restoration from merely recovering acoustic signal input to reconstructing full auditory function.”
Xu Wentao, lead researcher and professor at Nankai University
In animal trials, the system demonstrated success: deaf rabbits implanted with the interface regained the capacity to recognize spoken commands and complete matching tasks. The research team, which consists of over 40 members with an average age under 30, has spent eight years working on artificial neuromorphic nerves. Their prior work includes the development of the world’s first flexible artificial tactile nerve, reported in the journal Science in 2018.
Regenerative Approaches at the University of Sheffield
While the Nankai University team focuses on bionic interfaces, researchers at the University of Sheffield are pursuing a biological solution to sensorineural hearing loss (SNHL). SNHL occurs when hair cells in the cochlea—which convert sound waves into electrical signals—or their associated auditory neurons are damaged. Because humans are born with a finite number of these cells that do not regenerate, current clinical options are limited to managing symptoms via hearing aids or cochlear implants rather than curing the underlying damage.
A spin-out company from the university, Rinri Therapeutics, is developing a regenerative cell therapy called Rincell-1. Unlike gene therapy, which targets faulty genetic code, this approach involves injecting stem cell-derived progenitor cells into the ear to replace dysfunctional auditory nerve cells. Since its formation in 2018, the company has secured over £20 million in funding from global investors, including the Boehringer Ingelheim Venture Fund and the UK Future Fund. The company plans to initiate its first human trial for Rincell-1 in 2025.
Computational Advances in Sign Language Recognition
For individuals whose hearing loss remains unaddressed by current medical interventions, advancements in assistive technology continue to evolve. A study explores the HHODLM-SLR technique, an artificial intelligence-based method for sign language recognition. This system utilizes a deep residual network—ResNet-152—to classify complex hand gestures.
The research emphasizes the use of bilateral filtering (BF) to pre-process images, which removes environmental noise while preserving edge sharpness—a critical requirement for interpreting hand shapes accurately. By combining deep learning architectures with hyperparameter tuning, the researchers aim to improve the precision of automated detection systems. This digital approach complements physical restoration efforts, providing a parallel path for improving the quality of life for those with speech and hearing impairments.
Clinical Outlook and Future Trials
The road to widespread clinical application remains the next hurdle for these diverse technologies. For the team at Nankai University, the focus has shifted toward industrial transformation and upcoming clinical trials. Their bionic auditory interface is intended to integrate into broader medical neuroprosthetics, potentially bridging the gap between biological hearing and machine-based signal processing. Meanwhile, the upcoming 2025 human trials for Rinri Therapeutics’ Rincell-1 will serve as a critical test for the viability of regenerative cell therapy in human auditory rehabilitation.
Keep reading